Unmet Needs and Future Directions in Care in CLL
Closing out their discussion on novel treatment strategies in CLL, expert hematologist-oncologists address unmet needs and future directions in care.
Chronic Lymphocytic Leukemia: Emerging Therapeutic Targets
An in-depth review of novel therapeutic targets making their way into clinical trials for patients with chronic lymphocytic leukemia.
Optimal Sequencing of Therapy in Chronic Lymphocytic Leukemia
Following their discussion on novel therapeutic agents in chronic lymphocytic leukemia, panelists consider how these agents might be sequenced for optimal efficacy.
Evolving Role of Anti-CD20 Therapy in Chronic Lymphocytic Leukemia
Expert perspectives on the novel use of ant-CD20 therapy as first-line or combination treatment in chronic lymphocytic leukemia.
Novel Strategies in Managing Patients With High-Risk Chronic Lymphocytic Leukemia
Key opinion leaders provide their perspective on the optimal management of high-risk chronic lymphocytic leukemia with novel therapeutic agents.
Venetoclax + Second Generation BTKi Combination Therapy in R/R CLL
Clinical trial updates evaluating the combination of venetoclax with second-generation BTK inhibitors acalabrutinib and zanabrutinib, respectively.
Clinical Trials in R/R CLL: Venetoclax + Ibrutinib Combination Therapy
Key updates from clinical trials evaluating the combination of venetoclax and ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia.
Fixed Duration Venetoclax Therapy in Relapsed/Refractory CLL
Centering focus on the relapsed/refractory setting of CLL, panelists consider the use of fixed-duration venetoclax following updated clinical trial data in this setting.
Non-Covalent BTK Inhibitors in CLL: Updates from Clinical Trials With Pirtobrutinib
Expert perspectives on the role of non-covalent BTK inhibitors in managing patients diagnosed with chronic lymphocytic leukemia.
Chronic Lymphocytic Leukemia: Real World and QoL Evidence With BTKi
A panel of key opinion leaders elucidates real-world data with BTK inhibitors in CLL and considers the importance of patient-reported outcomes on quality of life.
Selecting the Appropriate BTKi in Chronic Lymphocytic Leukemia
Comprehensive perspectives on clinical factors that help to inform the selection of appropriate BTK inhibitor therapy for patients with chronic lymphocytic leukemia.
Head-to-Head Trials of BTKi in Chronic Lymphocytic Leukemia
Shared insight on and reactions to head-to-head comparison trials between novel BTK inhibitors in the setting of chronic lymphocytic leukemia.
BTK Inhibitors in Relapsed/Refractory Chronic Lymphocytic Leukemia
Switching focus to the second-line setting, expert hematologist-oncologists evaluate the continued role of BTK inhibitors in chronic lymphocytic leukemia.
Second Generation BTKi in CLL: First-Line Treatment With Acalabrutinib or Zanubrutinib
Centering discussion on second-generation BTK inhibitors, expert panelists review clinical data behind first-line acalabrutinib and zanubrutinib, respectively.
Chronic Lymphocytic Leukemia: Role of First-Generation BTK Inhibitors
A brief review of first-line BTK inhibition in chronic lymphocytic leukemia following the advent of ibrutinib, along with considerations for minimal residual disease testing in this setting.
Brief Overview of Chronic Lymphocytic Leukemia
Expert hematologist-oncologist Sonali Smith, MD, shares a brief overview of chronic lymphocytic leukemia (CLL), highlighting incidence, prognosis, and molecular subsets.
Dr. Jacobs on the Continued Impact of the CAPTIVATE trial in CLL
Ryan Jacobs, MD, discusses the implications of next-line treatment strategies following long-term data of the phase 2 CAPTIVATE trial in chronic lymphocytic leukemia.
Dr. Jacobs on Treating Graft-Versus-Host-Disease With Ibrutinib in CLL
Ryan W. Jacobs, MD, physician, Levine Cancer Institute, discusses the use of ibrutinib (Imbruvica) in treating chronic graft-versus-host disease in patients with chronic lymphocytic leukemia (CLL).
Dr. Jacobs Discusses the Frontline Treatment of CLL
Ryan W. Jacobs, MD, physician, Levine Cancer Institute, discusses the frontline treatment of patients with chronic lymphocytic leukemia.
Dr. Jacobs on the Efficacy of Ibrutinib and Acalabrutinib in Patients With MCL
Ryan W. Jacobs, MD, physician, Levine Cancer Institute, discusses the efficacy of ibrutinib (Imbruvica) and acalabrutinib (Calquence) in patients with mantle cell lymphoma (MCL).
Dr. Jacobs on the Use of Ibrutinib in High-Risk Patients With CLL
Ryan W. Jacobs, MD, physician, Levine Cancer Institute, discusses the use of ibrutinib (Imbruvica) in high-risk patients with chronic lymphocytic leukemia (CLL).
Further Understanding of Immune Mechanisms in Tumor Microenvironment Is Key to Advancing Immunotherapy in Solid Tumors
Navigating Systemic Therapy for RCC: Balancing Risk Status and Response
ADCs, Novel Targets Represent Next Wave of Treatment Advances in mCRPC
Precision Medicine in Prostate Cancer Care: Keeping Up With Evolving Guidance for Testing and Decision Making
2 Clarke Drive Cranbury, NJ 08512